Login Register Cart 0
Generic placeholder image

Current Aging Science

Editor-in-Chief

ISSN (Print): 1874-6098
ISSN (Online): 1874-6128

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Role of Nutraceuticals and Physical Activity in Parkinson's Disease Risk and Lifestyle Management

Author(s): Pranay Wal, Himangi Vig, Ankita Wal*, Shruti Rathore, Shiv Shanker Pandey, Nem Kumar Jain and Ashish Srivastava

Volume 16, Issue 3, 2023

Published on: 12 June, 2023

Page: [170 - 187] Pages: 18

DOI: 10.2174/1874609816666230515121717

Price: $65

Abstract

Background: Parkinson's disease is a complicated, gradually progressive neurological illness characterized by locomotor and non-motor symptomatology that impedes daily activities. Despite significant advances in symptomatic therapies with various extents of negative effects, there are currently no disease-modifying medicinal alternatives. Symptoms worsen, creating an additional strain that reduces living quality and creates the perception that prescription drugs are no longer productive.

Objective: Adopting healthy lifestyle habits can help patients feel more empowered, promote wellness, relieve symptoms, and potentially slow neurodegeneration. Nutrition, intellectual stimulation, physical exercise, and stress reduction are all examples of lifestyle habits that improve cognitive health and life satisfaction. We discuss how changes in lifestyle, nutrition, yoga, exercise, and acupuncture can help with managing the disease's symptoms.

Methods: We searched Google Scholar for various research papers and review articles from publishers, such as Bentham Science, Elsevier, Taylor and Francis, Springer Nature, and others for gathering the data for the study.

Results: Pesticide exposure, environmental hazards, dietary choices, stress, and anxiety all have an indirect or immediate influence on the commencement of Parkinson's disease. Naturopathic remedies, such as nutraceuticals, yoga, exercise, and acupuncture, have been shown to help with Parkinson's disease management.

Conclusion: Various preclinical and clinical studies have shown that the various factors mentioned are beneficial in the management of the disease, but more research is needed to validate the extent to which such factors are beneficial.

« Previous Next »
Graphical Abstract

[1]
Wal P, Dwivedi J, Wal A, Vig H, Singh Y. Detailed insight into the pathophysiology and the behavioral complications associated with the Parkinson’s disease and its medications. Future Pharmac Sci 2022; 8(1): 33.
[http://dx.doi.org/10.1186/s43094-022-00425-5]
[2]
Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol 2020; 19(2): 170-8.
[http://dx.doi.org/10.1016/S1474-4422(19)30287-X] [PMID: 31521533]
[3]
De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey E. Preventing parkinson’s disease: an environmental agenda. J Parkinsons Dis 2021; 12(1): 45-68.
[4]
Cenci MA, Björklund A. Animal models for preclinical Parkinson’s research: An update and critical appraisal. Prog Brain Res 2020; 252: 27-59.
[http://dx.doi.org/10.1016/bs.pbr.2020.02.003]] [PMID: 32247366]
[5]
Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s disease: Current status and future developments. Curr Neuropharmacol 2018; 16(8): 1239-52.
[http://dx.doi.org/10.2174/1570159X15666170510143821] [PMID: 28494719]
[6]
Carrera I, Cacabelos R. Current drugs and potential future neuroprotective compounds for Parkinson’s disease. Curr Neuropharmacol 2019; 17(3): 295-306.
[http://dx.doi.org/10.2174/1570159X17666181127125704] [PMID: 30479218]
[7]
Lister T. Nutrition and lifestyle interventions for managing Parkinson’s disease: A narrative review. J Mov Disord 2020; 13(2): 97-104.
[http://dx.doi.org/10.14802/jmd.20006] [PMID: 32498495]
[8]
Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: Focus on astrocytes. Mol Neurobiol 2014; 49(1): 28-38.
[http://dx.doi.org/10.1007/s12035-013-8483-x] [PMID: 23783559]
[9]
Zhang Z, Wang M, Yuan S, Larsson SC, Liu X. Genetically predicted milk intake and risk of neurodegenerative diseases. Nutrients 2021; 13(8): 2893.
[http://dx.doi.org/10.3390/nu13082893] [PMID: 34445060]
[10]
Caballero M, Amiri S, Denney J, Monsivais P, Hystad P, Amram O. Estimated residential exposure to agricultural chemicals and premature mortality by Parkinson’s disease in Washington state. Int J Environ Res Public Health 2018; 15(12): 2885.
[http://dx.doi.org/10.3390/ijerph15122885] [PMID: 30558363]
[11]
Ciulla M, Marinelli L, Cacciatore I, Stefano AD. Role of dietary supplements in the management of Parkinson’s disease. Biomolecules 2019; 9(7): 271.
[http://dx.doi.org/10.3390/biom9070271] [PMID: 31295842]
[12]
Shahnawaz M, Mukherjee A, Pritzkow S, et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 2020; 578(7794): 273-7.
[http://dx.doi.org/10.1038/s41586-020-1984-7] [PMID: 32025029]
[13]
Matheoud D, Cannon T, Voisin A, et al. Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1-/- mice. Nature 2019; 571(7766): 565-9.
[http://dx.doi.org/10.1038/s41586-019-1405-y] [PMID: 31316206]
[14]
Suárez-Iglesias D, Santos L, Sanchez-Lastra MA, Ayán C. Systematic review and meta-analysis of randomised controlled trials on the effects of yoga in people with Parkinson’s disease. Disabil Rehabil 2022; 44(21): 6210-29.
[PMID: 34533097]
[15]
Cheung C, Bhimani R, Wyman JF, et al. Effects of yoga on oxidative stress, motor function, and non-motor symptoms in Parkinson’s disease: A pilot randomized controlled trial. Pilot Feasibility Stud 2018; 4(1): 162.
[http://dx.doi.org/10.1186/s40814-018-0355-8] [PMID: 30377537]
[16]
Lee SH, Lim S. Clinical effectiveness of acupuncture on Parkinson disease. Medicine (Baltimore) 2017; 96(3): e5836.
[http://dx.doi.org/10.1097/MD.0000000000005836] [PMID: 28099340]
[17]
Noh H, Kwon S, Cho SY, et al. Effectiveness and safety of acupuncture in the treatment of Parkinson’s disease: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med 2017; 34: 86-103.
[http://dx.doi.org/10.1016/j.ctim.2017.08.005] [PMID: 28917379]
[18]
Brandín-de la Cruz N, Calvo S, Rodríguez-Blanco C, Herrero P, Bravo-Esteban E. Effects of dry needling on gait and muscle tone in Parkinson’s disease: A randomized clinical trial. Acupunct Med 2022; 40(1): 3-12.
[http://dx.doi.org/10.1177/09645284211039232] [PMID: 34541889]
[19]
Sohn SA, Lee KY, Kim CW, Lee YJ. Acupuncture treatment in clinical studies for parkinson’s disease: A literature review. Journal of Acupuncture Research 2018; 35(4): 149-57.
[http://dx.doi.org/10.13045/jar.2018.00157]
[20]
van Uem JMT, Marinus J, Canning C, et al. Health-Related Quality of Life in patients with Parkinson’s disease—A systematic review based on the ICF model. Neurosci Biobehav Rev 2016; 61: 26-34.
[http://dx.doi.org/10.1016/j.neubiorev.2015.11.014] [PMID: 26645499]
[21]
Hermanowicz N, Jones SA, Hauser RA. Impact of non-motor symptoms in Parkinson’s disease: A PMDAlliance survey. Neuropsychiatr Dis Treat 2019; 15: 2205-12.
[http://dx.doi.org/10.2147/NDT.S213917] [PMID: 31496703]
[22]
Mathur S, Mursaleen L, Stamford J, DeWitte S, Robledo I, Isaacs T. Challenges of improving patient-centred care in Parkinson’s disease. J Parkinsons Dis 2017; 7(1): 163-74.
[http://dx.doi.org/10.3233/JPD-160922] [PMID: 27858720]
[23]
Marras C, Canning CG, Goldman SM. Environment, lifestyle, and Parkinson’s disease: Implications for prevention in the next decade. Mov Disord 2019; 34(6): 801-11.
[http://dx.doi.org/10.1002/mds.27720] [PMID: 31091353]
[24]
Abeliovich A, Gitler AD. Defects in trafficking bridge Parkinson’s disease pathology and genetics. Nature 2016; 539(7628): 207-16.
[http://dx.doi.org/10.1038/nature20414] [PMID: 27830778]
[25]
Nandipati S, Litvan I. Environmental exposures and Parkinson’s disease. Int J Environ Res Public Health 2016; 13(9): 881.
[http://dx.doi.org/10.3390/ijerph13090881] [PMID: 27598189]
[26]
Yin W, Löf M, Pedersen NL, Sandin S, Fang F. Mediterranean dietary pattern at middle age and risk of Parkinson’s disease: A Swedish cohort study. Mov Disord 2021; 36(1): 255-60.
[http://dx.doi.org/10.1002/mds.28314] [PMID: 33078857]
[27]
Liu C, Liu Z, Zhang Z, et al. A Scientometric analysis and visualization of research on Parkinson’s disease associated with pesticide exposure. Front Public Health 2020; 8: 91.
[http://dx.doi.org/10.3389/fpubh.2020.00091] [PMID: 32318533]
[28]
Liu C, Fang J, Liu W. Superoxide dismutase coding of gene polymorphisms associated with susceptibility to Parkinson’s disease. J Integr Neurosci 2019; 18(3): 299-303.
[http://dx.doi.org/10.31083/j.jin.2019.03.127] [PMID: 31601079]
[29]
Lulla A, Barnhill L, Bitan G, et al. Neurotoxicity of the Parkinson disease-associated pesticide ziram is synuclein-dependent in zebrafish embryos. Environ Health Perspect 2016; 124(11): 1766-75.
[http://dx.doi.org/10.1289/EHP141] [PMID: 27301718]
[30]
Chen H, Marder K. Milk consumption and the risk of nigral degeneration. Neurology 2016; 86(6): 496-7.
[http://dx.doi.org/10.1212/WNL.0000000000002268] [PMID: 26658908]
[31]
Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 2020; 36(1): 1-12.
[http://dx.doi.org/10.1016/j.cger.2019.08.002] [PMID: 31733690]
[32]
Barnhill LM, Murata H, Bronstein JM. Studying the pathophysiology of Parkinson’s disease using zebrafish. Biomedicines 2020; 8(7): 197.
[http://dx.doi.org/10.3390/biomedicines8070197] [PMID: 32645821]
[33]
Sharma RK, Candelario-Jalil E, Feineis D, Bringmann G, Fiebich BL, Akundi RS. 1-Trichloromethyl-1, 2, 3, 4-tetrahydro-beta-carboline (TaClo) alters cell cycle progression in human neuroblastoma cell lines. Neurotox Res 2017; 32(4): 649-60.
[http://dx.doi.org/10.1007/s12640-017-9782-1] [PMID: 28721631]
[34]
Li Y, Xie C, Murphy SK, et al. Lead exposure during early human development and DNA methylation of imprinted gene regulatory elements in adulthood. Environ Health Perspect 2016; 124(5): 666-73.
[http://dx.doi.org/10.1289/ehp.1408577] [PMID: 26115033]
[35]
Araújo ML, Gomes BC, Devóz PP, et al. Association Between miR-148a and DNA Methylation Profile in Individuals Exposed to Lead (Pb). Front Genet 2021; 12: 620744.
[http://dx.doi.org/10.3389/fgene.2021.620744] [PMID: 33679885]
[36]
Salmanzadeh H, Ahmadi-Soleimani SM, Azadi M, Halliwell RF, Azizi H. Adolescent substance abuse, transgenerational consequences and epigenetics. Curr Neuropharmacol 2021; 19(9): 1560-9.
[http://dx.doi.org/10.2174/1570159X19666210303121519] [PMID: 33655865]
[37]
Reichmann H, Csoti I, Koschel J, et al. Life style and Parkinson’s disease. J Neural Transm (Vienna) 2022; 129(9): 1235-45.
[http://dx.doi.org/10.1007/s00702-022-02509-1] [PMID: 35606622]
[38]
Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson’s disease: A systematic review and meta-analysis. Neuroepidemiology 2016; 46(4): 292-300.
[http://dx.doi.org/10.1159/000445751] [PMID: 27105081]
[39]
Domenighetti C, Sugier PE, Ashok Kumar Sreelatha A, et al. Dairy Intake and Parkinson’s Disease: A Mendelian Randomization Study. Mov Disord 2022; 37(4): 857-64.
[http://dx.doi.org/10.1002/mds.28902] [PMID: 34997937]
[40]
Olsson E, Byberg L, Höijer J, Kilander L, Larsson SC. Milk and fermented milk intake and Parkinson’s disease: Cohort study. Nutrients 2020; 12(9): 2763.
[http://dx.doi.org/10.3390/nu12092763] [PMID: 32927800]
[41]
Çelık RGG, Köksal A, Şahın B, Şen A, Sakalli NK, Nalbantoğlu M. The relationship between serum uric acid levels and clinical features in essential tremor. Noro Psikiyatri Arsivi 2020; 57(1): 33-6.
[http://dx.doi.org/10.5152/npa.2015.8763] [PMID: 32110148]
[42]
Fernandez RD, Campos JSP, Santos TOCG. Nutritional status and food consumption of patients with Parkinson disease. Arq Neuropsiquiatr 2021; 79(8): 676-81.
[http://dx.doi.org/10.1590/0004-282x-anp-2020-0053] [PMID: 34550185]
[43]
Anderson GS, Di Nota PM, Metz GAS, Andersen JP. The impact of acute stress physiology on skilled motor performance: Implications for policing. Front Psychol 2019; 10: 2501.
[http://dx.doi.org/10.3389/fpsyg.2019.02501] [PMID: 31781001]
[44]
Neylan TC. Post-traumatic Stress Disorder and Neurodegeneration. Am J Geriatr Psychiatry 2020; 28(1): 61-3.
[http://dx.doi.org/10.1016/j.jagp.2019.09.002] [PMID: 31585690]
[45]
Fang X, Han D, Chen Q, et al. Association of levels of physical activity with risk of parkinson disease: A systematic review and meta-analysis. JAMA Netw Open 2018; 1(5): e182421.
[46]
Corcos DM, Robichaud JA, David FJ, et al. A two-year randomized controlled trial of progressive resistance exercise for Parkinson’s disease. Mov Disord 2013; 28(9): 1230-40.
[http://dx.doi.org/10.1002/mds.25380] [PMID: 23536417]
[47]
Hirsch MA, Iyer SS, Sanjak M. Exercise-induced neuroplasticity in human Parkinson’s disease: What is the evidence telling us? Parkinsonism Relat Disord 2016; 22 (Suppl. 1): S78-81.
[http://dx.doi.org/10.1016/j.parkreldis.2015.09.030] [PMID: 26439945]
[48]
Gallo V, Vineis P, Cancellieri M, et al. Exploring causality of the association between smoking and Parkinson’s disease. Int J Epidemiol 2019; 48(3): 912-25.
[PMID: 30462234]
[49]
Lee Y, Oh JS, Chung SJ, et al. Does smoking impact dopamine neuronal loss in de novo Parkinson disease? Ann Neurol 2017; 82(5): 850-4.
[http://dx.doi.org/10.1002/ana.25082] [PMID: 29059491]
[50]
Oertel W, Müller H, Schade-Brittinger C, et al. The NIC-PDstudy–a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and N. America. Mov Disord 2018; 33: 5159.
[51]
Marras C, Hincapié CA, Kristman VL, et al. Systematic review of the risk of Parkinson’s disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Arch Phys Med Rehabil 2014; 95(3): S238-44.
[http://dx.doi.org/10.1016/j.apmr.2013.08.298] [PMID: 24581909]
[52]
Taylor KM, Saint-Hilaire MH, Sudarsky L, et al. Head injury at early ages is associated with risk of Parkinson’s disease. Parkinsonism Relat Disord 2016; 23: 57-61.
[http://dx.doi.org/10.1016/j.parkreldis.2015.12.005] [PMID: 26725141]
[53]
Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: A systematic review and meta-analysis. Mov Disord 2013; 28(9): 1222-9.
[http://dx.doi.org/10.1002/mds.25458] [PMID: 23609436]
[54]
Briguglio M, Dell’Osso B, Panzica G, et al. Dietary neurotransmitters: A narrative review on current knowledge. Nutrients 2018; 10(5): 591.
[http://dx.doi.org/10.3390/nu10050591] [PMID: 29748506]
[55]
Worku D, Matt R. The role of the gut in Parkinsons disease. Eur Exp Biol 2019; 9(2): 6.
[56]
Mittal R, Debs LH, Patel AP, et al. Neurotransmitters: The critical modulators regulating gut–brain axis. J Cell Physiol 2017; 232(9): 2359-72.
[http://dx.doi.org/10.1002/jcp.25518] [PMID: 27512962]
[57]
Mulak A, Koszewicz M, Panek-Jeziorna M, Koziorowska-Gawron E, Budrewicz S. Fecal calprotectin as a marker of the gut immune system activation is elevated in Parkinson’s disease. Front Neurosci 2019; 13: 992.
[http://dx.doi.org/10.3389/fnins.2019.00992] [PMID: 31611762]
[58]
Benítez-Páez A, Kjølbæk L, Gómez del Pulgar EM, et al. A multi-omics approach to unraveling the microbiome-mediated effects of arabinoxylan oligosaccharides in overweight humans. mSystems 2019; 4(4): e00209-19.
[http://dx.doi.org/10.1128/mSystems.00209-19] [PMID: 31138673]
[59]
Mihaila D, Donegan J, Barns S, et al. The oral microbiome of early stage Parkinson’s disease and its relationship with functional measures of motor and non-motor function. PLoS One 2019; 14(6): e0218252.
[http://dx.doi.org/10.1371/journal.pone.0218252] [PMID: 31247001]
[60]
Ye S, Kim H, Jeong-Choi K, et al. Parkinson’s disease among firefighters: A focused review on the potential effects of exposure to toxic chemicals at the fire scene. Korean J Biol Psychiatry 2017; 24(1): 19-25.
[61]
Goyal V, Radhakrishnan DM. Parkinson’s disease: A review. Neurol India 2018; 66(7)(Suppl.): 26.
[http://dx.doi.org/10.4103/0028-3886.226451] [PMID: 29503325]
[62]
Cheng Q, Liu QQ, Li K, Chang CH, Lu CA. Assessing Dietary Pesticide Intake and Potential Health Effects: The Application of Global Metabolomics Analysis. J Agric Food Chem 2022; 70(13): 4086-91.
[http://dx.doi.org/10.1021/acs.jafc.1c08050] [PMID: 35320672]
[63]
Murray LK, Jadavji NM. The role of one-carbon metabolism and homocysteine in Parkinson’s disease onset, pathology and mechanisms. Nutr Res Rev 2019; 32(2): 218-30.
[http://dx.doi.org/10.1017/S0954422419000106] [PMID: 31303188]
[64]
Kim JH, Hwang J, Shim E, Chung EJ, Jang SH, Koh SB. Association of serum carotenoid, retinol, and tocopherol concentrations with the progression of Parkinson’s disease. Nutr Res Pract 2017; 11(2): 114-20.
[http://dx.doi.org/10.4162/nrp.2017.11.2.114] [PMID: 28386384]
[65]
Leskovec J, Levart A, Perić L, et al. Antioxidative effects of supplementing linseed oil-enriched diets with α-tocopherol, ascorbic acid, selenium, or their combination on carcass and meat quality in broilers. Poult Sci 2019; 98(12): 6733-41.
[http://dx.doi.org/10.3382/ps/pez389] [PMID: 31318430]
[66]
Song MK, Lee JH, Kim J, et al. Neuroprotective effect of NXP031 in the MPTP-induced Parkinson’s disease model. Neurosci Lett 2021; 740: 135425.
[http://dx.doi.org/10.1016/j.neulet.2020.135425] [PMID: 33075422]
[67]
Rakowski M. Porębski S, Grzelak A. Nutraceuticals as Modulators of Autophagy: Relevance in Parkinson’s Disease. Int J Mol Sci 2022; 23(7): 3625.
[http://dx.doi.org/10.3390/ijms23073625] [PMID: 35408992]
[68]
Barichella M, Garrì F, Caronni S, et al. Vitamin D Status and Parkinson’s Disease. Brain Sci 2022; 12(6): 790.
[http://dx.doi.org/10.3390/brainsci12060790] [PMID: 35741675]
[69]
Rebas E, Rzajew J, Radzik T, Zylinska L. Neuroprotective polyphenols: A modulatory action on neurotransmitter pathways. Curr Neuropharmacol 2020; 18(5): 431-45.
[http://dx.doi.org/10.2174/1570159X18666200106155127] [PMID: 31903883]
[70]
Negida A, Menshawy A, El Ashal G, et al. Coenzyme Q10 for patients with Parkinson’s disease: A systematic review and meta-analysis. CNS Neurol Disord Drug Targets 2016; 15(1): 45-53.
[http://dx.doi.org/10.2174/1871527314666150821103306] [PMID: 26553164]
[71]
Percário S, da Silva Barbosa A, Varela ELP, et al. Oxidative stress in parkinson’s disease: Potential benefits of antioxidant supplementation. Oxid Med Cell Longev 2020; 2020: 1-23.
[http://dx.doi.org/10.1155/2020/2360872] [PMID: 33101584]
[72]
Srivastav S, Fatima M, Mondal AC. Important medicinal herbs in Parkinson’s disease pharmacotherapy. Biomed Pharmacother 2017; 92: 856-63.
[http://dx.doi.org/10.1016/j.biopha.2017.05.137] [PMID: 28599249]
[73]
Shen Q, Bi X, Ling L, Ding W. 1, 25-Dihydroxyvitamin D3 attenuates angiotensin II-induced renal injury by inhibiting mitochondrial dysfunction and autophagy. Cell Physiol Biochem 2018; 51(4): 1751-62.
[http://dx.doi.org/10.1159/000495678] [PMID: 30504714]
[74]
Javed H, Nagoor Meeran MF, Azimullah S, Adem A, Sadek B, Ojha SK. Plant extracts and phytochemicals targeting α-synuclein aggregation in Parkinson’s disease models. Front Pharmacol 2019; 9: 1555.
[http://dx.doi.org/10.3389/fphar.2018.01555] [PMID: 30941047]
[75]
Barcelos RP, Stefanello ST, Mauriz JL, Gonzalez-Gallego J, Soares FAA. Creatine and the liver: metabolism and possible interactions. Mini Rev Med Chem 2015; 16(1): 12-8.
[http://dx.doi.org/10.2174/1389557515666150722102613] [PMID: 26202197]
[76]
Mustapha M, Mat Taib CN. MPTP-induced mouse model of Parkinson’s disease: A promising direction of therapeutic strategies. Bosn J Basic Med Sci 2021; 21(4): 422-33.
[PMID: 33357211]
[77]
El Barky AR, Hussein SA, Mohamed TM. The potent antioxidant alpha lipoic acid. J Plant Chem Ecophysiol 2017; 2: 1016.
[78]
Baluchnejadmojarad T, Rabiee N, Zabihnejad S, Roghani M. Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson’s disease: Possible involvement of ERβ/Nrf2/HO-1 signaling. Brain Res 2017; 1662: 23-30.
[http://dx.doi.org/10.1016/j.brainres.2017.02.021] [PMID: 28238669]
[79]
Karunaratne TB, Okereke C, Seamon M, Purohit S, Wakade C, Sharma A. Niacin and butyrate: Nutraceuticals targeting dysbiosis and intestinal permeability in parkinson’s disease. Nutrients 2020; 13(1): 28.
[http://dx.doi.org/10.3390/nu13010028] [PMID: 33374784]
[80]
de Carvalho FO, Silva JPR, Silva ÉR, de Albuquerque Júnior RLC, Nunes PS, de Souza Araújo AA. Would carvacrol be a supporting treatment option effective in minimizing the deleterious effects of COVID-19? Naunyn Schmiedebergs Arch Pharmacol 2021; 394(12): 2471-4.
[http://dx.doi.org/10.1007/s00210-021-02170-7] [PMID: 34669001]
[81]
Haddadi H, Rajaei Z, Alaei H, Shahidani S. Chronic treatment with carvacrol improves passive avoidance memory in a rat model of Parkinson’s disease. Arq Neuropsiquiatr 2018; 76(2): 71-7.
[http://dx.doi.org/10.1590/0004-282x20170193] [PMID: 29489959]
[82]
Taghizadeh M, Tamtaji OR, Dadgostar E, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Neurochem Int 2017; 108: 183-9.
[http://dx.doi.org/10.1016/j.neuint.2017.03.014] [PMID: 28342967]
[83]
Shukla M, Govitrapong P, Boontem P, Reiter RJ, Satayavivad J. Mechanisms of melatonin in alleviating Alzheimer’s disease. Curr Neuropharmacol 2017; 15(7): 1010-31.
[PMID: 28294066]
[84]
Šic Žlabur J, Voća S, Dobričević N, et al. Ultrasound-assisted extraction of bioactive compounds from lemon balm and peppermint leaves. Int Agrophys 2016; 30(1): 95-104.
[http://dx.doi.org/10.1515/intag-2015-0077]
[85]
Chang MC, Kwak SG, Kwak S. Effect of dietary vitamins C and E on the risk of Parkinson’s disease: A meta-analysis. Clin Nutr 2021; 40(6): 3922-30.
[http://dx.doi.org/10.1016/j.clnu.2021.05.011] [PMID: 34139465]
[86]
Kruk J. Szymańska R. Singlet oxygen oxidation products of carotenoids, fatty acids and phenolic prenyllipids. J Photochem Photobiol B 2021; 216: 112148.
[http://dx.doi.org/10.1016/j.jphotobiol.2021.112148] [PMID: 33556703]
[87]
Ezzat SM, Ezzat MI, Okba MM, Menze ET, Abdel-Naim AB. The hidden mechanism beyond ginger (Zingiber officinale Rosc.) potent in vivo and in vitro anti-inflammatory activity. J Ethnopharmacol 2018; 214: 113-23.
[http://dx.doi.org/10.1016/j.jep.2017.12.019] [PMID: 29253614]
[88]
Alsahli MA, Almatroodi SA, Almatroudi A, et al. 6-Gingerol, a major ingredient of ginger attenuates diethylnitrosamine-induced liver injury in rats through the modulation of oxidative stress and anti-inflammatory activity. Mediators Inflamm 2021; 2021: 6661937.
[89]
Chang KH, Cheng ML, Chiang MC, Chen CM. Lipophilic antioxidants in neurodegenerative diseases. Clin Chim Acta 2018; 485: 79-87.
[http://dx.doi.org/10.1016/j.cca.2018.06.031] [PMID: 29940147]
[90]
Scheperjans F. Gut microbiota, 1013 new pieces in the Parkinson’s disease puzzle. Curr Opin Neurol 2016; 29(6): 773-80.
[http://dx.doi.org/10.1097/WCO.0000000000000389] [PMID: 27653288]
[91]
Zhang N. Role of methionine on epigenetic modification of DNA methylation and gene expression in animals. Anim Nutr 2018; 4(1): 11-6.
[http://dx.doi.org/10.1016/j.aninu.2017.08.009] [PMID: 30167479]
[92]
Varshney KK, Gupta JK, Mujwar S. Homocysteine induced neurological dysfunctions: A link to neurodegenerative disorders. Int J Med Res Health Sci 2019; 8: 135-46.
[93]
Zhao Y, Tian D, Guo N, et al. Investigating the causality of metabolites involved in one-carbon metabolism with the risk and age at onset of Parkinson’s disease: A two-sample mendelian randomization study. Neurobiol Aging 2021; 108: 196-9.
[http://dx.doi.org/10.1016/j.neurobiolaging.2021.06.023] [PMID: 34325950]
[94]
Kalampokini S, Becker A, Fassbender K, Lyros E, Unger MM. Nonpharmacological modulation of chronic inflammation in Parkinson’s disease: role of diet interventions. Parkinsons Dis 2019; 2019: 1-12.
[http://dx.doi.org/10.1155/2019/7535472] [PMID: 31534664]
[95]
Agarwal P, Wang Y, Buchman AS, Holland TM, Bennett DA, Morris MC. MIND diet associated with reduced incidence and delayed progression of Parkinsonism in old age. J Nutr Health Aging 2018; 22(10): 1211-5.
[http://dx.doi.org/10.1007/s12603-018-1094-5] [PMID: 30498828]
[96]
Zhao X, Zhang M, Li C, Jiang X, Su Y, Zhang Y. Benefits of vitamins in the treatment of Parkinson’s disease. Oxid Med Cell Longev 2019; 2019: 1-14.
[http://dx.doi.org/10.1155/2019/9426867] [PMID: 30915197]
[97]
Subramanian VS, Teafatiller T, Agrawal A, Kitazawa M, Marchant JS. Effect of lipopolysaccharide and TNFα on neuronal ascorbic acid uptake. Mediators Inflamm 2021; 2021: 1-11.
[http://dx.doi.org/10.1155/2021/4157132] [PMID: 34285658]
[98]
Li R, Zhang Y, Rasool S, Geetha T, Babu JR. Effects and underlying mechanisms of bioactive compounds on type 2 diabetes mellitus and Alzheimer’s disease. Oxid Med Cell Longev 2019; 2019: 1-25.
[http://dx.doi.org/10.1155/2019/8165707] [PMID: 30800211]
[99]
Lorente-Picón M, Laguna A. New avenues for Parkinson’s Disease therapeutics: Disease-modifying strategies based on the gut microbiota. Biomolecules 2021; 11(3): 433.
[http://dx.doi.org/10.3390/biom11030433] [PMID: 33804226]
[100]
Ysselstein D, Nguyen M, Young TJ, et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients. Nat Commun 2019; 10(1): 5570.
[http://dx.doi.org/10.1038/s41467-019-13413-w] [PMID: 31804465]
[101]
Kang SY, Lee SB, Kim HJ, Kim HT, Yang HO, Jang W. Autophagic modulation by rosuvastatin prevents rotenone-induced neurotoxicity in an in vitro model of Parkinson’s disease. Neurosci Lett 2017; 642: 20-6.
[http://dx.doi.org/10.1016/j.neulet.2017.01.063] [PMID: 28137648]
[102]
Pakrashi S, Chakraborty J, Bandyopadhyay J. Neuroprotective role of quercetin on rotenone-induced toxicity in SH-SY5Y cell line through modulation of apoptotic and autophagic pathways. Neurochem Res 2020; 45(8): 1962-73.
[http://dx.doi.org/10.1007/s11064-020-03061-8] [PMID: 32488468]
[103]
Habtemariam S. The Nrf2/HO-1 axis as targets for flavanones: neuroprotection by pinocembrin, naringenin, and eriodictyol. Oxid Med Cell Longev 2019; 2019: 1-15.
[http://dx.doi.org/10.1155/2019/4724920] [PMID: 31814878]
[104]
Dominiak A, Wilkaniec A. Wroczyński P, Adamczyk A. Selenium in the therapy of neurological diseases. Where is it going? Curr Neuropharmacol 2016; 14(3): 282-99.
[http://dx.doi.org/10.2174/1570159X14666151223100011] [PMID: 26549649]
[105]
Sharma S, Nozohouri S, Vaidya B, Abbruscato T. Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke. Life Sci 2021; 274: 119343.
[http://dx.doi.org/10.1016/j.lfs.2021.119343] [PMID: 33716063]
[106]
Filograna R, Beltramini M, Bubacco L, Bisaglia M. Anti-oxidants in Parkinson’s disease therapy: A critical point of view. Curr Neuropharmacol 2016; 14(3): 260-71.
[http://dx.doi.org/10.2174/1570159X13666151030102718] [PMID: 26517052]
[107]
Lindskov S, Sjöberg K, Hagell P, Westergren A. Weight stability in Parkinson’s disease. Nutr Neurosci 2016; 19(1): 11-20.
[http://dx.doi.org/10.1179/1476830515Y.0000000044] [PMID: 26339843]
[108]
Gammella E, Recalcati S, Cairo G. Dual role of ROS as signal and stress agents: Iron tips the balance in favor of toxic effects. Oxid Med Cell Longev 2016; 2016: 1-9.
[http://dx.doi.org/10.1155/2016/8629024] [PMID: 27006749]
[109]
Youdim MBH. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. J Neural Transm (Vienna) 2018; 125(11): 1719-33.
[http://dx.doi.org/10.1007/s00702-018-1942-9] [PMID: 30341696]
[110]
McAllum EJ, Finkelstein DI. Metals in Alzheimer’s and Parkinson’s disease: Relevance to dementia with lewy bodies. J Mol Neurosci 2016; 60(3): 279-88.
[http://dx.doi.org/10.1007/s12031-016-0809-5] [PMID: 27498879]
[111]
Behl T, Madaan P, Sehgal A, et al. Mechanistic insights expatiating the redox-active-metal-mediated neuronal degeneration in Parkinson’s disease. Int J Mol Sci 2022; 23(2): 678.
[http://dx.doi.org/10.3390/ijms23020678] [PMID: 35054862]
[112]
Das B, Rajagopalan S, Joshi GS, et al. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo. Neuropharmacology 2017; 123: 88-99.
[http://dx.doi.org/10.1016/j.neuropharm.2017.05.019] [PMID: 28533164]
[113]
Abeyawardhane DL, Lucas HR. Iron redox chemistry and implications in the Parkinson’s disease brain. Oxid Med Cell Longev 2019; 2019: 1-11.
[http://dx.doi.org/10.1155/2019/4609702] [PMID: 31687080]
[114]
Chen L, Lin Z, Wang M, et al. Treatment of trauma-induced femoral head necrosis with biodegradable pure Mg screw-fixed pedicle iliac bone flap. J Orthop Translat 2019; 17: 133-7.
[http://dx.doi.org/10.1016/j.jot.2019.01.004] [PMID: 31194045]
[115]
Chen C, Turnbull DM, Reeve AK. Mitochondrial dysfunction in Parkinson’s disease—cause or consequence? Biology (Basel) 2019; 8(2): 38.
[http://dx.doi.org/10.3390/biology8020038] [PMID: 31083583]
[116]
Oggiano R, Solinas G, Forte G, et al. Trace elements in ALS patients and their relationships with clinical severity. Chemosphere 2018; 197: 457-66.
[http://dx.doi.org/10.1016/j.chemosphere.2018.01.076] [PMID: 29366958]
[117]
Forni C, Facchiano F, Bartoli M, et al. Beneficial role of phytochemicals on oxidative stress and age-related diseases. BioMed Res Int 2019; 2019: 1-16.
[http://dx.doi.org/10.1155/2019/8748253] [PMID: 31080832]
[118]
Pérez-Otaño I, Larsen RS, Wesseling JF. Emerging roles of GluN3-containing NMDA receptors in the CNS. Nat Rev Neurosci 2016; 17(10): 623-35.
[http://dx.doi.org/10.1038/nrn.2016.92] [PMID: 27558536]
[119]
Niemann N, Jankovic J. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord 2019; 67: 74-89.
[http://dx.doi.org/10.1016/j.parkreldis.2019.06.025] [PMID: 31272925]
[120]
McCarty MF, Lerner A. Nutraceuticals targeting generation and oxidant activity of peroxynitrite may aid prevention and control of Parkinson’s disease. Int J Mol Sci 2020; 21(10): 3624.
[http://dx.doi.org/10.3390/ijms21103624] [PMID: 32455532]
[121]
Balachandran RC, Mukhopadhyay S, McBride D, et al. Brain manganese and the balance between essential roles and neurotoxicity. J Biol Chem 2020; 295(19): 6312-29.
[http://dx.doi.org/10.1074/jbc.REV119.009453] [PMID: 32188696]
[122]
Lin X, Xu X, Zeng X, Xu L, Zeng Z, Huo X. Decreased vaccine antibody titers following exposure to multiple metals and metalloids in e-waste-exposed preschool children. Environ Pollut 2017; 220(Pt A): 354-63.
[http://dx.doi.org/10.1016/j.envpol.2016.09.071 ] [PMID: 27692881]
[123]
Ayaz M, Sadiq A, Junaid M, et al. Flavonoids as prospective neuroprotectants and their therapeutic propensity in aging associated neurological disorders. Front Aging Neurosci 2019; 11: 155.
[http://dx.doi.org/10.3389/fnagi.2019.00155] [PMID: 31293414]
[124]
Ghavipour M, Sotoudeh G, Tavakoli E, Mowla K, Hasanzadeh J, Mazloom Z. Pomegranate extract alleviates disease activity and some blood biomarkers of inflammation and oxidative stress in Rheumatoid Arthritis patients. Eur J Clin Nutr 2017; 71(1): 92-6.
[http://dx.doi.org/10.1038/ejcn.2016.151] [PMID: 27577177]
[125]
Yang H, Wang Z, Song W, Zhao Z, Zhao Y. Isolation of proanthocyanidins from Pinus thunbergii needles and tyrosinase inhibition activity. Process Biochem 2021; 100: 245-51.
[http://dx.doi.org/10.1016/j.procbio.2020.10.003]
[126]
Zhu H, Song D, Zhao X. Potential applications and preliminary mechanism of action of dietary polyphenols against hyperuricemia: A review. Food Biosci 2021; 43: 101297.
[http://dx.doi.org/10.1016/j.fbio.2021.101297]
[127]
Nakajima A, Ohizumi Y. Potential benefits of nobiletin, a citrus flavonoid, against Alzheimer’s disease and Parkinson’s disease. Int J Mol Sci 2019; 20(14): 3380.
[http://dx.doi.org/10.3390/ijms20143380] [PMID: 31295812]
[128]
Timmers MA, Grace MH, Yousef GG, Lila MA. Inter- and intra-seasonal changes in anthocyanin accumulation and global metabolite profiling of six blueberry genotypes. J Food Compos Anal 2017; 59: 105-10.
[http://dx.doi.org/10.1016/j.jfca.2017.02.019]
[129]
Madeira MH, Boia R, Ambrósio AF, Santiago AR. Having a coffee break: The impact of caffeine consumption on microglia-mediated inflammation in neurodegenerative diseases. Mediators Inflamm 2017; 2017: 1-12.
[http://dx.doi.org/10.1155/2017/4761081] [PMID: 28250576]
[130]
Li P, Feng D, Yang D, et al. Protective effects of anthocyanins on neurodegenerative diseases. Trends Food Sci Technol 2021; 117: 205-17.
[http://dx.doi.org/10.1016/j.tifs.2021.05.005]
[131]
Schepici G, Silvestro S, Bramanti P, Mazzon E. Caffeine: An overview of its beneficial effects in experimental models and clinical trials of parkinson’s disease. Int J Mol Sci 2020; 21(13): 4766.
[http://dx.doi.org/10.3390/ijms21134766] [PMID: 32635541]
[132]
Boulos C, Yaghi N, El Hayeck R, Heraoui GNHA, Fakhoury-Sayegh N. Nutritional risk factors, microbiota and Parkinson’s disease: what is the current evidence? Nutrients 2019; 11(8): 1896.
[http://dx.doi.org/10.3390/nu11081896] [PMID: 31416163]
[133]
Shakleina M, Bogatova I, Vartanov S, et al. Socioeconomic determinants of Parkinson’s disease for developed and developing countries. Econom Matem Method 2020; 56(4): 53-66.
[http://dx.doi.org/10.31857/S042473880012424-5]
[134]
Palakurthi B, Burugupally SP. Postural instability in Parkinson’s disease: A review. Brain Sci 2019; 9(9): 239.
[http://dx.doi.org/10.3390/brainsci9090239] [PMID: 31540441]
[135]
Ren X, Chen JF. Caffeine and Parkinson’s disease: multiple benefits and emerging mechanisms. Front Neurosci 2020; 14: 602697.
[http://dx.doi.org/10.3389/fnins.2020.602697] [PMID: 33390888]
[136]
Mischley LK. Nutrition and nonmotor symptoms of Parkinson’s disease. Int Rev Neurobiol 2017; 134: 1143-61.
[http://dx.doi.org/10.1016/bs.irn.2017.04.013] [PMID: 28805567]
[137]
Price BR, Wilcock DM, Weekman EM. Hyperhomocysteinemia as a risk factor for vascular contributions to cognitive impairment and dementia. Front Aging Neurosci 2018; 10: 350.
[http://dx.doi.org/10.3389/fnagi.2018.00350] [PMID: 30429785]
[138]
Ceppa FA, Izzo L, Sardelli L, et al. Human gut-microbiota interaction in neurodegenerative disorders and current engineered tools for its modeling. Front Cell Infect Microbiol 2020; 10: 297.
[http://dx.doi.org/10.3389/fcimb.2020.00297] [PMID: 32733812]
[139]
Codagnone MG, Stanton C, O’Mahony SM, Dinan TG, Cryan JF. Microbiota and neurodevelopmental trajectories: role of maternal and early-life nutrition. Ann Nutr Metab 2019; 74(2) (Suppl. 2): 16-27.
[http://dx.doi.org/10.1159/000499144] [PMID: 31234188]
[140]
Arotcarena ML, Dovero S, Prigent A, et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain 2020; 143(5): 1462-75.
[http://dx.doi.org/10.1093/brain/awaa096] [PMID: 32380543]
[141]
Cassani E, Privitera G, Pezzoli G, et al. Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterol Dietol 2011; 57(2): 117-21.
[PMID: 21587143]
[142]
van Kessel SP, Frye AK, El-Gendy AO, et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat Commun 2019; 10(1): 310.
[http://dx.doi.org/10.1038/s41467-019-08294-y] [PMID: 30659181]
[143]
Srivastav S, Neupane S, Bhurtel S, et al. Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. J Nutr Biochem 2019; 69: 73-86.
[http://dx.doi.org/10.1016/j.jnutbio.2019.03.021] [PMID: 31063918]
[144]
Qiao CM, Sun MF, Jia XB, et al. Sodium butyrate causes α-synuclein degradation by an Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway. Exp Cell Res 2020; 387(1): 111772.
[http://dx.doi.org/10.1016/j.yexcr.2019.111772] [PMID: 31836471]
[145]
Provancha-Romeo AF, Hoffman AL, Malcolm MP, et al. Mind-body interventions utilized by an occupational therapist in a medical intensive care unit: An exploratory case study. Work 2019; 63(2): 191-7.
[http://dx.doi.org/10.3233/WOR-192920] [PMID: 31156200]
[146]
Nivethitha L, Manjunath NK, Mooventhan A. Heart rate variability changes during and after the practice of bhramari pranayama. Int J Yoga 2017; 10(2): 99-102.
[http://dx.doi.org/10.4103/0973-6131.205518] [PMID: 28546681]
[147]
Ni M, Mooney K, Signorile JF. Controlled pilot study of the effects of power yoga in Parkinson’s disease. Complement Ther Med 2016; 25: 126-31.
[http://dx.doi.org/10.1016/j.ctim.2016.01.007] [PMID: 27062960]
[148]
Cherup NP, Strand KL, Lucchi L, Wooten SV, Luca C, Signorile JF. Yoga meditation enhances proprioception and balance in individuals diagnosed with Parkinson’s disease. Percept Mot Skills 2021; 128(1): 304-23.
[http://dx.doi.org/10.1177/0031512520945085] [PMID: 32746736]
[149]
Legault Z, Znaty A, Smith S, Boudrias MH. Yoga Interventions used for the rehabilitation of stroke, Parkinson’s disease, and multiple sclerosis: A scoping review of clinical research. J Altern Complement Med 2021; 27(12): 1023-57.
[http://dx.doi.org/10.1089/acm.2021.0003] [PMID: 34185577]
[150]
Mooventhan A, Nivethitha L. Evidence based effects of yoga in neurological disorders. J Clin Neurosci 2017; 43: 61-7.
[http://dx.doi.org/10.1016/j.jocn.2017.05.012] [PMID: 28599839]
[151]
Colgrove YM, Sharma NK, Robbins K, Wagner K. A randomized controlled pilot study of the therapeutic effects of yoga in people with Parkinson's disease. Int J Yoga 2015; 8(1): 74-9.
[http://dx.doi.org/10.4103/0973-6131.146070] [PMID: 25558138]
[152]
Mailankody P, Varambally S, Thennarasu K, Pal PK. The Rationale of Yoga in Parkinson’s Disease: A Critical Review. Neurol India 2021; 69(5): 1165-75.
[PMID: 34747780]
[153]
Jasti N, Bhargav H, Babu H, Nagarathna R. Challenging case in clinical practice: Yoga therapy for Parkinson’s disease. Altern Complement Ther 2020; 26(2): 57-60.
[http://dx.doi.org/10.1089/act.2020.29264.nja]
[154]
Meigal AY, Tretjakova OG, Gerasimova-Meigal LI, Sayenko IV. Program of seven 45-min dry immersion sessions improves choice reaction time in Parkinson’s disease. Front Physiol 2021; 11: 621198.
[http://dx.doi.org/10.3389/fphys.2020.621198] [PMID: 33519524]
[155]
Hill HM, Swink LA, Atler KE, Anderson AK, Fling BW, Schmid AA. Merging Yoga and Occupational Therapy for Parkinson’s Disease improves fatigue management and activity and participation measures. Br J Occup Ther 2021; 84(4): 230-9.
[http://dx.doi.org/10.1177/0308022620909086]
[156]
LaHue SC, Comella CL, Tanner CM. The best medicine? The influence of physical activity and inactivity on Parkinson’s disease. Mov Disord 2016; 31(10): 1444-54.
[http://dx.doi.org/10.1002/mds.26728] [PMID: 27477046]
[157]
Lai JH, Chen KY, Wu JCC, et al. Voluntary exercise delays progressive deterioration of markers of metabolism and behavior in a mouse model of Parkinson’s disease. Brain Res 2019; 1720: 146301.
[http://dx.doi.org/10.1016/j.brainres.2019.146301] [PMID: 31226324]
[158]
Hou L, Chen W, Liu X, Qiao D, Zhou FM. Exercise-induced neuroprotection of the nigrostriatal dopamine system in Parkinson’s disease. Front Aging Neurosci 2017; 9: 358.
[http://dx.doi.org/10.3389/fnagi.2017.00358] [PMID: 29163139]
[159]
Zhou W, Barkow JC, Freed CR. Running wheel exercise reduces α-synuclein aggregation and improves motor and cognitive function in a transgenic mouse model of Parkinson’s disease. PLoS One 2017; 12(12): e0190160.
[http://dx.doi.org/10.1371/journal.pone.0190160] [PMID: 29272304]
[160]
García-Muñoz C, González-García P, Casuso-Holgado MJ, Martínez-Calderón J, Heredia-Rizo AM. Are movement-based mindful exercises (QIGONG, TAI CHI, AND YOGA) beneficial for stroke and Parkinson’s disease? A scoping review. Complement Ther Med 2023; 72: 102912.
[http://dx.doi.org/10.1016/j.ctim.2022.102912] [PMID: 36565791]
[161]
Ban M, Yue X, Dou P, Zhang P. The effects of yoga on patients with Parkinson’s disease: A meta-analysis of randomized controlled trials. Behav Neurol 2021; 2021: 1-11.
[http://dx.doi.org/10.1155/2021/5582488] [PMID: 34285724]
[162]
Vera-Garcia FJ. Exercise prescription in patients with chronic diseases. Eur J Sport Sci 2018; 41: 1-5.
[163]
Mak MK, Wong-Yu IS, Shen X, Chung CL. Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol 2017; 13(11): 689-703.
[http://dx.doi.org/10.1038/nrneurol.2017.128] [PMID: 29027544]
[164]
Stuckenschneider T, Askew CD, Menêses AL, Baake R, Weber J, Schneider S. The effect of different exercise modes on domain-specific cognitive function in patients suffering from Parkinson’s disease: A systematic review of randomized controlled trials. J Parkinsons Dis 2019; 9(1): 73-95.
[http://dx.doi.org/10.3233/JPD-181484] [PMID: 30741688]
[165]
Shin MS, Kim TW, Lee JM, Ji ES, Lim BV. Treadmill exercise alleviates nigrostriatal dopaminergic loss of neurons and fibers in rotenone-induced Parkinson rats. J Exerc Rehabil 2017; 13(1): 30-5.
[http://dx.doi.org/10.12965/jer.1734906.453] [PMID: 28349030]
[166]
Taubert M, Villringer A, Lehmann N. Endurance exercise as an “endogenous” neuro-enhancement strategy to facilitate motor learning. Front Hum Neurosci 2015; 9: 692.
[http://dx.doi.org/10.3389/fnhum.2015.00692] [PMID: 26834602]
[167]
Schenkman M, Moore CG, Kohrt WM, et al. Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: A phase 2 randomized clinical trial. JAMA Neurol 2018; 75(2): 219-26.
[http://dx.doi.org/10.1001/jamaneurol.2017.3517] [PMID: 29228079]
[168]
Flach A, Jaegers L, Krieger M, et al. Endurance exercise improves function in individuals with Parkinson’s disease: A meta-analysis. Neurosci Lett 2017; 659: 115-9.
[http://dx.doi.org/10.1016/j.neulet.2017.08.076] [PMID: 28870627]
[169]
Uygur M, Bellumori M, Knight CA. Effects of a low-resistance, interval bicycling intervention in Parkinson’s Disease. Physiother Theory Pract 2017; 33(12): 897-904.
[http://dx.doi.org/10.1080/09593985.2017.1359868] [PMID: 28812404]
[170]
Tong W, Zhang K, Yao H, et al. Transcriptional Profiling Reveals Brain Region-Specific Gene Networks Regulated in Exercise in a Mouse Model of Parkinson’s Disease. Front Aging Neurosci 2022; 14: 891644.
[http://dx.doi.org/10.3389/fnagi.2022.891644] [PMID: 35813950]
[171]
Cheng X, Yu Z, Hu W, et al. Voluntary exercise ameliorates neuropathic pain by suppressing calcitonin gene-related peptide and ionized calcium-binding adapter molecule 1 overexpression in the lumbar dorsal horns in response to injury to the cervical spinal cord. Exp Neurol 2022; 354: 114105.
[http://dx.doi.org/10.1016/j.expneurol.2022.114105] [PMID: 35525308]
[172]
Chul Jang Y, Hwang DJ, Koo JH, et al. Association of exercise-induced autophagy upregulation and apoptosis suppression with neuroprotection against pharmacologically induced Parkinson’s disease. J Exerc Nutrition Biochem 2018; 22(1): 1.
[173]
Liu W, Li L, Liu S, et al. MicroRNA expression profiling screen miR-3557/324-targeted CaMK/mTOR in the rat striatum of Parkinson’s disease in regular aerobic exercise. BioMed Res Int 2019; 2019: 1-12.
[http://dx.doi.org/10.1155/2019/7654798]
[174]
Engeroff T, Vogt L, Fleckenstein J, et al. Lifespan leisure physical activity profile, brain plasticity and cognitive function in old age. Aging Ment Health 2019; 23(7): 811-8.
[http://dx.doi.org/10.1080/13607863.2017.1421615] [PMID: 29293024]
[175]
Yu SW, Lin SH, Tsai CC, et al. Acupuncture effect and mechanism for treating pain in patients with Parkinson’s disease. Front Neurol 2019; 10: 1114.
[http://dx.doi.org/10.3389/fneur.2019.01114] [PMID: 31695670]
[176]
Cao L, Li X, Li M, et al. The effectiveness of acupuncture for Parkinson’s disease: An overview of systematic reviews. Complement Ther Med 2020; 50: 102383.
[http://dx.doi.org/10.1016/j.ctim.2020.102383] [PMID: 32444048]
[177]
Cheng FK. The use of acupuncture in patients with Parkinson’s disease. Geriatr Nurs 2017; 38(4): 302-14.
[http://dx.doi.org/10.1016/j.gerinurse.2016.11.010] [PMID: 28041638]
[178]
Li S, Dong J, Cheng C, Le W. Therapies for Parkinson’s diseases: Alternatives to current pharmacological interventions. J Neural Transm (Vienna) 2016; 123(11): 1279-99.
[http://dx.doi.org/10.1007/s00702-016-1603-9] [PMID: 27515029]
[179]
Weintraub D, Aarsland D, Chaudhuri KR, et al. The neuropsychiatry of Parkinson’s disease: Advances and challenges. Lancet Neurol 2022; 21(1): 89-102.
[http://dx.doi.org/10.1016/S1474-4422(21)00330-6] [PMID: 34942142]
[180]
Cho SY, Lee YE, Doo KH, et al. Efficacy of combined treatment with acupuncture and bee venom acupuncture as an adjunctive treatment for Parkinson’s disease. J Altern Complement Med 2018; 24(1): 25-32.
[http://dx.doi.org/10.1089/acm.2016.0250] [PMID: 28753030]
[181]
Li L, Jin X, Cong W, Du T, Zhang W. Acupuncture in the treatment of parkinson’s disease with sleep disorders and dose response. Biomed Res Int 2022; 2022: 1-7.
[182]
Chen FP, Chang CM, Shiu JH, et al. A clinical study of integrating acupuncture and Western medicine in treating patients with Parkinson’s disease. Am J Chin Med 2015; 43(3): 407-23.
[http://dx.doi.org/10.1142/S0192415X15500263] [PMID: 25967661]
[183]
Zhang R, Li J, Wu Y, Liang S, Xu L. Association of multiple dopamine D3 receptor gene 3′UTR polymorphisms with susceptibility to Parkinson’s disease and clinical efficacy of piribedil therapy. Genet Test Mol Biomarkers 2021; 25(1): 20-30.
[http://dx.doi.org/10.1089/gtmb.2020.0195] [PMID: 33372861]
[184]
Forogh B, Rafiei M, Arbabi A, Motamed MR, Madani SP, Sajadi S. Repeated sessions of transcranial direct current stimulation evaluation on fatigue and daytime sleepiness in Parkinson’s disease. Neurol Sci 2017; 38(2): 249-54.
[http://dx.doi.org/10.1007/s10072-016-2748-x] [PMID: 27796604]
[185]
Danqing X. Acupuncture for Parkinson’s Disease: A review of clinical, animal, and functional Magnetic Resonance Imaging studies. J Tradit Chin Med 2015; 35(6): 709-17.
[http://dx.doi.org/10.1016/S0254-6272(15)30164-3] [PMID: 26742319]
[186]
Fan JQ, Lu WJ, Tan WQ, Feng WC, Zhuang LX. Acupuncture for Parkinson’s disease: From theory to practice. Biomed Pharmacother 2022; 149: 112907.
[http://dx.doi.org/10.1016/j.biopha.2022.112907] [PMID: 35366533]
[187]
Del Tredici K, Braak H. To stage, or not to stage. Curr Opin Neurobiol 2020; 61: 10-22.
[http://dx.doi.org/10.1016/j.conb.2019.11.008] [PMID: 31862625]
[188]
Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol 2020; 27(1): 27-42.
[http://dx.doi.org/10.1111/ene.14108] [PMID: 31631455]
[189]
Yeo S, van den Noort M, Bosch P, Lim S. A study of the effects of 8-week acupuncture treatment on patients with Parkinson’s disease. Medicine (Baltimore) 2018; 97(50): e13434.
[http://dx.doi.org/10.1097/MD.0000000000013434] [PMID: 30557997]
[190]
Muhammad F, Liu Y, Zhou Y, Yang H, Li H. Antioxidative role of Traditional Chinese Medicine in Parkinson’s disease. J Ethnopharmacol 2022; 285: 114821.
[http://dx.doi.org/10.1016/j.jep.2021.114821] [PMID: 34838943]
[191]
Fukuda S, Kuriyama N, Egawa M. Acupuncture for Gait Disturbance in Parkinson’s Disease: Immediate Effects of Acupuncture Treatment. J Am Geriatr Soc 2015; 63(10): 2189-90.
[http://dx.doi.org/10.1111/jgs.13690] [PMID: 26480983]
[192]
Toosizadeh N, Lei H, Schwenk M, et al. Does integrative medicine enhance balance in aging adults? Proof of concept for the benefit of electroacupuncture therapy in Parkinson’s disease. Gerontology 2015; 61(1): 3-14.
[http://dx.doi.org/10.1159/000363442] [PMID: 25341431]
[193]
Lei H, Toosizadeh N, Schwenk M, et al. A Pilot Clinical Trial to Objectively Assess the Efficacy of Electroacupuncture on Gait in Patients with Parkinson’s Disease Using Body Worn Sensors. PLoS One 2016; 11(5): e0155613.
[http://dx.doi.org/10.1371/journal.pone.0155613] [PMID: 27227460]
[194]
Doo KH, Lee JH, Cho SY, et al. A Prospective Open-Label Study of Combined Treatment for Idiopathic Parkinson’s Disease Using Acupuncture and Bee Venom Acupuncture as an Adjunctive Treatment. J Altern Complement Med 2015; 21(10): 598-603.
[http://dx.doi.org/10.1089/acm.2015.0078] [PMID: 26230989]
[195]
Eng ML, Lyons KE, Greene MS, Pahwa R. Open-label trial regarding the use of acupuncture and yin tui na in Parkinson’s disease outpatients: A pilot study on efficacy, tolerability, and quality of life. J Altern Complement Med 2006; 12(4): 395-9.
[http://dx.doi.org/10.1089/acm.2006.12.395] [PMID: 16722790]
[196]
Shulman LM, Wen X, Weiner WJ, et al. Acupuncture therapy for the symptoms of Parkinson’s disease. Mov Disord 2002; 17(4): 799-802.
[http://dx.doi.org/10.1002/mds.10134] [PMID: 12210879]
[197]
Kluger BM, Rakowski D, Christian M, et al. Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson’s Disease. Mov Disord 2016; 31(7): 1027-32.
[http://dx.doi.org/10.1002/mds.26597] [PMID: 27028133]
[198]
Kong KH, Ng HL, Li W, et al. Acupuncture in the treatment of fatigue in Parkinson’s disease: A pilot, randomized, controlled, study. Brain Behav 2018; 8(1): e00897.
[http://dx.doi.org/10.1002/brb3.897] [PMID: 29568693]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy